Abstract:Rare eye diseases encompass a broad spectrum of genetic anomalies with or without additional extraocular manifestations. Genetic eye disorders in pediatric patients often lead to severe visual impairments. Therefore, a challenge of gene therapy is to provide better vision to these affected children. In recent years, inherited retinal diseases, inherited optic neuropathies, and corneal dystrophies have dominated discussions to establish gene and cell replacement therapies for these diseases. Gene therapy involves the transfer of genetic material to remove, replace, repair, or introduce a gene, or to overexpress a protein, whose activity would have a therapeutic impact. For the majority of anterior segment diseases, these studies are still emerging at a preclinical stage; however, for inherited retinal disorders, translation has been reached, leading to the introduction of the first gene therapies into clinical practice. In the past decade, the first gene therapy for biallelic RPE65-mediated inherited retinal dystrophy has been developed and the FDA and EMA both approved ocular gene therapy. Other promising approaches by intravitreal injection have been investigated such as in CEP290-Leber congenital amaurosis. Various techniques of gene therapies include gene supplementation, CRISPR-based genome editing, as well as RNA modulation and optogenetics. Optogenetic therapies deliver light-activated ion channels to surviving retinal cell types in order to restore photosensitivity. Beyond retinal function, ataluren, a nonsense mutation suppression therapy, enables ribosomal read-through of mRNA containing premature termination codons, resulting in the production of a full-length protein. An ophthalmic formulation was recently evaluated with the aim of repairing corneal damage, pending new clinical studies. However, various congenital disorders exhibit severe developmental defects or cell loss at birth, limiting the potential for viral gene therapy. Therefore mutation-independent strategies seem promising for maintaining the survival of photoreceptors or for restoring visual function. Restoring vision in children with gene therapy continues to be a challenge in ophthalmology. © 2023 Published by Elsevier Masson SAS on behalf of French Society of Pediatrics.

Emerging Therapeutic Approaches and Genetic Insights in Stargardt Disease: A Comprehensive Review

The ABCs of Stargardt disease: the latest advances in precision medicine

The Surviving, Not Thriving, Photoreceptors in Patients with ABCA4 Stargardt Disease

The progress in treatment of type 1 of Stargardt disease

Stargardt disease: Multimodal imaging: A review

Advances and Challenges in Gene Therapy for Inherited Retinal Dystrophies: A Comprehensive Review

Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology

Exploring Stem-Cell-Based Therapies for Retinal Regeneration

Gene-Based Therapeutics for Inherited Retinal Diseases

Advances in retina genetics: Progress, potential, and challenges

Clinical and Genetic Analyses Reveal Novel Pathogenic ABCA4 Mutations in Stargardt Disease Families

Clinical, phenotypic and genetic characteristics of macula‐sparing stargardt disease

Stem Cell Therapy for Inherited Retinal Diseases: a Systematic Review and Meta-Analysis

A Mini-Review on Gene Therapy in Glaucoma and Future Directions

The Progression of Stargardt Disease (ProgStar) as determined by spectral-domain optical coherence tomography over a 24-month period (ProgStar Report No. 19)

Navigating the Genetic Landscape: A Comprehensive Review of Novel Therapeutic Strategies for Retinitis Pigmentosa Management

Novel stem cell and gene therapy in diabetic retinopathy, age related macular degeneration, and retinitis pigmentosa

Update on gene therapies in pediatric ophthalmology

Review of gene therapies for age-related macular degeneration

Gene editing technology: Towards precision medicine in inherited retinal diseases

Unravelling the Fundamentals, Applications, and Future Perspectives